1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma. 2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. To assess correlation of METTL-14 expression with disease free survival and overall survival.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluation of immunohistochemical Expression of METTL14 in Type 1 Endometrial Carcinoma
Timeframe: baseline